Literature DB >> 15359723

Multidimensional protein profiling technology and its application to human plasma proteome.

Kiyonaga Fujii1, Tomoyo Nakano, Takeshi Kawamura, Fumihiko Usui, Yasuhiko Bando, Rong Wang, Toshihide Nishimura.   

Abstract

In clinical and diagnostic proteomics, it is essential to develop a comprehensive and robust system for proteome analysis. Although multidimensional liquid chromatography/tandem mass spectrometry (LC/MS/MS) systems have been recently developed as powerful tools especially for identification of protein complexes, these systems still some drawbacks in their application to clinical research that requires an analysis of a large number of human samples. Therefore, in this study, we have constructed a technically simple and high throughput protein profiling system comprising a two-dimensional (2D)-LC/MS/MS system which integrates both a strong cation exchange (SCX) chromatography and a microLC/MS/MS system with micro-flowing reversed-phase chromatography. Using the microLC/MS/MS system as the second dimensional chromatography, SCX separation has been optimized as an off-line first dimensional peptide fractionation. To evaluate the performance of the constructed 2D-LC/MS/MS system, the results of detection and identification of proteins were compared using digests mixtures of 6 authentic proteins with those obtained using one-dimensional microLC/MS/MS system. The number of peptide fragments detected and the coverage of protein sequence were found to be more than double through the use of our newly built 2D-LC/MS/MS system. Furthermore, this multidimensional protein profiling system has been applied to plasma proteome in order to examine its feasibility for clinical proteomics. The experimental results revealed the identification of 174 proteins from one serum sample depleted HSA and IgG which corresponds to only 1 microL of plasma, and the total analysis run time was less than half a day, indicating a fairly high possibility of practicing clinical proteomics in a high throughput manner.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15359723     DOI: 10.1021/pr030007q

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  7 in total

Review 1.  Disease proteomics toward bedside reality.

Authors:  Toshihide Nishimura; Atsushi Ogiwara; Kiyonaga Fujii; Takao Kawakami; Takeshi Kawamura; Hisae Anyouji; Harubumi Kato
Journal:  J Gastroenterol       Date:  2005-03       Impact factor: 7.527

2.  Protein separation and characterization by np-RP-HPLC followed by intact MALDI-TOF mass spectrometry and peptide mass mapping analyses.

Authors:  Claire Dauly; David H Perlman; Catherine E Costello; Mark E McComb
Journal:  J Proteome Res       Date:  2006-07       Impact factor: 4.466

3.  Extracellular proteome of human hepatoma cell, HepG2 analyzed using two-dimensional liquid chromatography coupled with tandem mass spectrometry.

Authors:  Ryo Yamashita; Yuko Fujiwara; Kohei Ikari; Keiko Hamada; Asuka Otomo; Kazuki Yasuda; Mitsuhiko Noda; Yasushi Kaburagi
Journal:  Mol Cell Biochem       Date:  2006-11-16       Impact factor: 3.396

Review 4.  Human body fluid proteome analysis.

Authors:  Shen Hu; Joseph A Loo; David T Wong
Journal:  Proteomics       Date:  2006-12       Impact factor: 3.984

5.  Synthesis and characterization of silica-based hyper-crosslinked sulfonate-modified reversed stationary phases.

Authors:  Hao Luo; Lianjia Ma; Yu Zhang; Peter W Carr
Journal:  J Chromatogr A       Date:  2007-12-07       Impact factor: 4.759

Review 6.  Prediction of individual response to anticancer therapy: historical and future perspectives.

Authors:  Florian T Unger; Irene Witte; Kerstin A David
Journal:  Cell Mol Life Sci       Date:  2014-11-12       Impact factor: 9.261

7.  Proteomic analysis of serum, plasma, and lymph for the identification of biomarkers.

Authors:  Zhaojing Meng; Timothy D Veenstra
Journal:  Proteomics Clin Appl       Date:  2007-07-13       Impact factor: 3.494

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.